[http://www.lmsoft.com/] CANCER REPORT, last update 2012 The oncological market is a challenge and combines more than other markets of the life science sector unique business opportunities with high risk. Targets technologies are under constant scrutiny and can quickly be replaced by novel techniques and approaches. The inherent expiration dates of target molecules and technologies compete with the 10-12 years time span needed to develop a new drug. The key factor to success for Biotech as well as for the pharmaceutical industry is excellent business development with a strong expertise in the scientific strategy behind a given therapeutic. The CANCER REPORT gives a snapshot of the state of the art. This report describes: · The cellular origins of various carcinomas · Molecular targets and · Presents a survey of more than 150 emerging novel therapeutics and their stage of development CANCER REPORT is unique in presenting the scientific background behind molecular targets and therapeutics addressing these targets. Thereby, the reports strongly supports and facilitates the evaluation of molecular targets and novel therapeutics. The CANCER REPORT can be purchased as a PDF file for € 300,- plus VAT or as a hard copy version for € 350,- plus VAT. Teaser CANCER REPORT
TECHNOLOGY CONSULTING Dr. Roswitha Gropp
[./homepag.html]
[./reportspag.html]
[./backgroundpag.html]
[./cnspag.html]
[./metabolicspag.html]
[./my_viewpag.html]
[./contactpag.html]
Home Background Reports CANCER CNS METABOLICS My View No Magic Bullets May 2006 Contact
[./homepag.html]
[./backgroundpag.html]
[./reportspag.html]
[./cnspag.html]
[./cancer_stem_cellspag.html]
[./contactpag.html]
[./my_viewpag.html]
[./metabolicspag.html]
[./my_viewpag.html]
Home Background Reports CANCER CNS METABOLICS CANCER STEM CELLS My View No Magic Bullets Contact